The economic value of personalized medicine tests: what we know and what we need to know.
about
Assessing the Costs and Cost-Effectiveness of Genomic SequencingEconomic evaluations of personalized medicine: existing challenges and current developmentsFrom big data analysis to personalized medicine for all: challenges and opportunitiesEpidemiology matters: peering inside the "black box" in economic evaluations of genetic testingEmerging roles for pharmacists in clinical implementation of pharmacogenomicsConcepts of 'personalization' in personalized medicine: implications for economic evaluation.Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Scenario drafting for early technology assessment of next generation sequencing in clinical oncologyWhen is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.Clinical Utility of a Comprehensive, Whole Genome CMA Testing Platform in Pediatrics: A Prospective Randomized Controlled Trial of Simulated Patients in Physician PracticesEconomic Evaluation in Stratified Medicine: Methodological Issues and ChallengesPersonalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard.Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.The economic considerations and implications of the stratification of future oncology therapeutics.Economics of stratified medicine in rheumatoid arthritis.Can genomic medicine improve financial sustainability of health systems?Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?"What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine.Towards integration of health economics into medical education and clinical practice in Saudi Arabia.Defining 'medical necessity' in an age of personalised medicine: A view from Canada.Rare disease prevention and treatment: the need for a level playing field.Next Generation Sequencing Methods for Diagnosis of Epilepsy Syndromes.Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective.Understanding barriers to the introduction of precision medicines in non-small cell lung cancer: A qualitative interview protocol.Precision Medicine: From Science To Value.Personalized medicines - are pharmacists ready for the challenge?Genomics research in Africa and its impact on global health: insights from African researchersFactors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review
P2860
Q26774155-14CFB528-F725-43BD-BFC9-A31F94F03A81Q26797183-1D005690-22F9-4081-859A-791F630127C3Q30976798-2BE38D3D-4C95-4040-9AB8-373A41DD0C8EQ33764223-99996909-D9D2-46D3-B94A-1D9F83147A13Q34302434-36A4CBD5-5BE8-493E-B45D-C5B80ABC8A79Q35575935-A4CFBC7F-F17B-4B87-A923-6C9A46761B87Q35681121-C4AC8A43-2757-4DDF-A6A4-213C5B79E4D5Q35890606-A1EA7BAD-ED49-4F68-970A-92D2DC64BD92Q35916535-A3BC56E7-A6BF-4F8B-8C4E-9367D82E92E3Q36157315-2372BF9C-17D9-4703-A6A1-4F99A5CAB67DQ36236352-65CF9E2D-1F5D-4AED-9EA2-35CF560147C9Q36883280-33657E6A-6BB4-4891-B94B-9E17C2AD2038Q37063857-6716B5AB-3C4C-4CC6-B9ED-53FDCF4F4C16Q37507366-794162FA-C236-4D28-8393-BBB8C9DB8D5CQ38211622-25E4488C-B0F1-4BA3-AC41-B49947D6D5F8Q38264743-4860F074-1349-4B75-853E-A8CE4EF3CDD8Q38415606-3D7B9154-21F1-4E36-BBF9-ED07E9A2246CQ38671676-CC45CC83-1C05-489B-8F09-D8016536A50CQ38756024-3C01BDE3-A90C-4F8C-BA8B-97C6925D0FE5Q38912161-89377508-A97A-4167-A053-730C97498C36Q40549451-0C019666-2AC1-4127-830B-7D1C32F89624Q47363206-187CBA30-FECE-4BCA-89A2-4D34F7E09090Q48050782-18ACA5DC-4979-438E-A6D4-A0A192A614ECQ48069953-365860B0-440C-4199-A005-1ADEE0AF1E98Q50071892-C627F055-DCCE-440C-828C-49453E40C94BQ52375104-6BD8E573-837B-4D21-835F-17C3BA184C88Q52690204-EFB4D56C-611E-4520-8736-73DA77E1295DQ55007332-0DBE1995-3A99-41CE-B61C-BCC70ECB9170Q55072280-E817B112-5B67-4155-8947-E3139AA1F4A3Q57492236-CF47F8E7-B78E-4E0D-A495-137F4DE30228Q57645238-BF9C90BC-00AE-40AC-B8DD-8E3F55B909CDQ58797089-5929B054-A552-41B1-9B45-B0C1FF0A715B
P2860
The economic value of personalized medicine tests: what we know and what we need to know.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The economic value of personalized medicine tests: what we know and what we need to know.
@en
The economic value of personalized medicine tests: what we know and what we need to know.
@nl
type
label
The economic value of personalized medicine tests: what we know and what we need to know.
@en
The economic value of personalized medicine tests: what we know and what we need to know.
@nl
prefLabel
The economic value of personalized medicine tests: what we know and what we need to know.
@en
The economic value of personalized medicine tests: what we know and what we need to know.
@nl
P2093
P2860
P356
P1433
P1476
The economic value of personalized medicine tests: what we know and what we need to know.
@en
P2093
Julia Trosman
Julie Ann Sakowski
Kathryn A Phillips
Michael P Douglas
Peter Neumann
Su-Ying Liang
P2860
P2888
P304
P356
10.1038/GIM.2013.122
P407
P577
2013-10-17T00:00:00Z